Table 2.
Selected molecular profiling initiatives and genotype matching to clinical trials
| Group | Sample size | Platform | Tissue sample | Germline control | Patients enrolled in genotype-matched trials | ORR of patients matched to treatment based on genotype |
|---|---|---|---|---|---|---|
| MSKCC [27] | 12,670 | 341–410 gene panels | FFPE | Yes | 527/5009 (10.5%) | Not available |
| DFCI-HCC [28] | 3727 | 275 gene panels | FFPE | No | 16/50 (32%) | Not available |
| Lyon [140, 141] | 2579 | 69 gene panels +aCGH | FFPE | Yes | 182/2579 (7%) | 13% |
| MDACC [26] | 2000 | 11–50 gene panels | FFPE | No | 83/2000 (4.2%) | Not available |
| Princess Margaret [25] | 1640 | 23–48 gene panels | FFPE | Yes | 92/1640 (5.6%) | 19% |
| Goustave Roussy [24] | 1035 | 30–75 gene panels + aCGH | Fresh biopsy | Yes | 199/1035 (19.2%) | 11% |
| Michigan [142] | 556 | WGS, WES, RNASeq | Fresh biopsy | Yes | 3–11% | Not available |
aCGH array comparative genomic hybridization, DFCI-HCC Dana Farber Cancer Institute-Harvard Cancer Center, FFPE formalin-fixed paraffin-embedded, MDACC MD Anderson Cancer Center, MSKCC Memorial Sloan Kettering Cancer Center, ORR objective response rate, WES whole exome sequencing, WGS whole genome sequencing